Text Size

One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease

Baudouin C., De La Maza M.S., Amrane M., Garrigue J.-S., Ismail D., Figueiredo F.C., Leonardi A.


  • 2017
  • European Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Quinze-Vingts National Ophthalmology Hospital, Paris, France; UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France; Institute Clinic of Ophthalmology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Santen SAS, Evry, France; Department of Ophthalmology, Royal Victoria Infirmary and Newcastle University, Newcastle upon Tyne, United Kingdom; Ophthalmology Unit, Department of Neuroscience, University of Padua, Padua, Italy

Related Publications

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.


Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.


Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022